Jasper Historical Financial Ratios

JSPR Stock

USD 4.99 0.25 4.77%

Jasper Therapeutics is lately reporting on over 97 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 5.31 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Jasper Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jasper Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Jasper Stock, please use our How to Invest in Jasper Therapeutics guide.

About Jasper Financial Ratios Analysis

Jasper TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Jasper Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Jasper financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Jasper Therapeutics history.

Jasper Therapeutics Financial Ratios Chart

At this time, Jasper Therapeutics' Price Book Value Ratio is relatively stable compared to the past year. As of 03/27/2025, Price Earnings To Growth Ratio is likely to grow to 0.18, while Operating Cash Flow Per Share is likely to drop (4.51).

Payables Turnover Cash Per Share Days Payables Outstanding Income Quality

Add Fundamental

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Income Quality

An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.

Most ratios from Jasper Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Jasper Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jasper Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Jasper Stock, please use our How to Invest in Jasper Therapeutics guide.At this time, Jasper Therapeutics' Price Book Value Ratio is relatively stable compared to the past year. As of 03/27/2025, Price Earnings To Growth Ratio is likely to grow to 0.18, while Operating Cash Flow Per Share is likely to drop (4.51).

	2022	2023	2024	2025 (projected)
Current Ratio	5.91	7.19	4.98	8.77
Net Debt To EBITDA	0.91	1.29	0.92	0.87

Current Ratio Net Debt To E B I T D A

Jasper Therapeutics fundamentals Correlations

	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Free Cash Flow Per Share	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Cash Per Share	Pocfratio	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets	Ev To Free Cash Flow	Earnings Yield	Intangibles To Total Assets	Net Debt To E B I T D A	Current Ratio
Ptb Ratio		0.75	0.26	0.85	-0.79	1.0	0.85	-0.84	0.82	-0.81	0.45	-0.81	-0.91	0.79	-0.91	-0.8	0.54	-0.67	-0.79	-0.28	-0.52	-0.79	0.43	0.7	-0.7	-0.61
Book Value Per Share	0.75		-0.11	0.93	-0.75	0.75	0.92	-0.98	0.97	-0.98	0.72	-0.73	-0.5	0.75	-0.48	-0.98	0.92	-0.62	-0.85	-0.64	-0.39	-0.85	0.67	0.98	-0.85	-0.66
Free Cash Flow Yield	0.26	-0.11		-0.12	0.22	0.26	-0.12	0.11	-0.15	0.13	-0.72	0.2	-0.6	-0.2	-0.6	0.17	-0.42	0.04	0.04	-0.26	-0.05	0.04	0.48	-0.01	0.12	0.23
Operating Cash Flow Per Share	0.85	0.93	-0.12		-0.94	0.85	1.0	-0.98	0.99	-0.98	0.77	-0.93	-0.57	0.94	-0.57	-0.98	0.82	-0.73	-0.87	-0.33	-0.51	-0.87	0.44	0.84	-0.85	-0.76
Capex To Depreciation	-0.79	-0.75	0.22	-0.94		-0.79	-0.95	0.87	-0.89	0.86	-0.79	1.0	0.49	-1.0	0.49	0.87	-0.67	0.73	0.77	-0.01	0.54	0.77	-0.13	-0.6	0.75	0.76
Pb Ratio	1.0	0.75	0.26	0.85	-0.79		0.85	-0.84	0.82	-0.81	0.45	-0.81	-0.91	0.79	-0.91	-0.8	0.54	-0.67	-0.79	-0.28	-0.52	-0.79	0.43	0.7	-0.7	-0.61
Free Cash Flow Per Share	0.85	0.92	-0.12	1.0	-0.95	0.85		-0.98	0.99	-0.98	0.77	-0.94	-0.57	0.95	-0.57	-0.98	0.81	-0.73	-0.87	-0.31	-0.51	-0.87	0.42	0.82	-0.85	-0.76
Inventory Turnover	-0.84	-0.98	0.11	-0.98	0.87	-0.84	-0.98		-1.0	1.0	-0.76	0.86	0.58	-0.87	0.56	1.0	-0.88	0.7	0.88	0.48	0.46	0.88	-0.55	-0.92	0.87	0.73
Net Income Per Share	0.82	0.97	-0.15	0.99	-0.89	0.82	0.99	-1.0		-1.0	0.79	-0.88	-0.54	0.89	-0.53	-1.0	0.88	-0.7	-0.88	-0.44	-0.47	-0.88	0.51	0.9	-0.87	-0.74
Days Of Inventory On Hand	-0.81	-0.98	0.13	-0.98	0.86	-0.81	-0.98	1.0	-1.0		-0.77	0.85	0.54	-0.86	0.53	1.0	-0.89	0.69	0.88	0.49	0.45	0.88	-0.56	-0.93	0.87	0.73
Payables Turnover	0.45	0.72	-0.72	0.77	-0.79	0.45	0.77	-0.76	0.79	-0.77		-0.77	-0.05	0.78	-0.04	-0.79	0.85	-0.53	-0.64	-0.07	-0.32	-0.64	-0.01	0.59	-0.67	-0.67
Cash Per Share	-0.81	-0.73	0.2	-0.93	1.0	-0.81	-0.94	0.86	-0.88	0.85	-0.77		0.51	-1.0	0.52	0.86	-0.65	0.73	0.77	-0.03	0.55	0.77	-0.11	-0.59	0.74	0.76
Pocfratio	-0.91	-0.5	-0.6	-0.57	0.49	-0.91	-0.57	0.58	-0.54	0.54	-0.05	0.51		-0.49	1.0	0.52	-0.24	0.48	0.58	0.3	0.41	0.58	-0.47	-0.52	0.46	0.38
Capex To Operating Cash Flow	0.79	0.75	-0.2	0.94	-1.0	0.79	0.95	-0.87	0.89	-0.86	0.78	-1.0	-0.49		-0.49	-0.87	0.66	-0.73	-0.77	0.01	-0.54	-0.77	0.14	0.6	-0.75	-0.76
Pfcf Ratio	-0.91	-0.48	-0.6	-0.57	0.49	-0.91	-0.57	0.56	-0.53	0.53	-0.04	0.52	1.0	-0.49		0.51	-0.22	0.48	0.57	0.27	0.41	0.57	-0.45	-0.5	0.45	0.37
Days Payables Outstanding	-0.8	-0.98	0.17	-0.98	0.87	-0.8	-0.98	1.0	-1.0	1.0	-0.79	0.86	0.52	-0.87	0.51		-0.9	0.69	0.87	0.47	0.45	0.87	-0.53	-0.92	0.87	0.73
Income Quality	0.54	0.92	-0.42	0.82	-0.67	0.54	0.81	-0.88	0.88	-0.89	0.85	-0.65	-0.24	0.66	-0.22	-0.9		-0.42	-0.82	-0.54	-0.42	-0.82	0.47	0.88	-0.86	-0.75
Roe	-0.67	-0.62	0.04	-0.73	0.73	-0.67	-0.73	0.7	-0.7	0.69	-0.53	0.73	0.48	-0.73	0.48	0.69	-0.42		0.32	0.13	-0.13	0.32	-0.24	-0.54	0.27	0.17
Ev To Operating Cash Flow	-0.79	-0.85	0.04	-0.87	0.77	-0.79	-0.87	0.88	-0.88	0.88	-0.64	0.77	0.58	-0.77	0.57	0.87	-0.82	0.32		0.41	0.81	1.0	-0.48	-0.8	0.99	0.92
Pe Ratio	-0.28	-0.64	-0.26	-0.33	-0.01	-0.28	-0.31	0.48	-0.44	0.49	-0.07	-0.03	0.3	0.01	0.27	0.47	-0.54	0.13	0.41		-0.01	0.41	-0.93	-0.78	0.43	0.11
Return On Tangible Assets	-0.52	-0.39	-0.05	-0.51	0.54	-0.52	-0.51	0.46	-0.47	0.45	-0.32	0.55	0.41	-0.54	0.41	0.45	-0.42	-0.13	0.81	-0.01		0.81	-0.12	-0.31	0.8	0.88
Ev To Free Cash Flow	-0.79	-0.85	0.04	-0.87	0.77	-0.79	-0.87	0.88	-0.88	0.88	-0.64	0.77	0.58	-0.77	0.57	0.87	-0.82	0.32	1.0	0.41	0.81		-0.48	-0.8	0.99	0.92
Earnings Yield	0.43	0.67	0.48	0.44	-0.13	0.43	0.42	-0.55	0.51	-0.56	-0.01	-0.11	-0.47	0.14	-0.45	-0.53	0.47	-0.24	-0.48	-0.93	-0.12	-0.48		0.78	-0.48	-0.19
Intangibles To Total Assets	0.7	0.98	-0.01	0.84	-0.6	0.7	0.82	-0.92	0.9	-0.93	0.59	-0.59	-0.52	0.6	-0.5	-0.92	0.88	-0.54	-0.8	-0.78	-0.31	-0.8	0.78		-0.8	-0.57
Net Debt To E B I T D A	-0.7	-0.85	0.12	-0.85	0.75	-0.7	-0.85	0.87	-0.87	0.87	-0.67	0.74	0.46	-0.75	0.45	0.87	-0.86	0.27	0.99	0.43	0.8	0.99	-0.48	-0.8		0.93
Current Ratio	-0.61	-0.66	0.23	-0.76	0.76	-0.61	-0.76	0.73	-0.74	0.73	-0.67	0.76	0.38	-0.76	0.37	0.73	-0.75	0.17	0.92	0.11	0.88	0.92	-0.19	-0.57	0.93

Click cells to compare fundamentals

Jasper Therapeutics Account Relationship Matchups

Jasper Therapeutics fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Income Quality	0.58	1.1	1.22	0.81	0.88	0.66
Roe	0.9	(0.35)	(0.67)	(0.82)	(0.95)	(0.9)
Ev To Operating Cash Flow	(0.52)	(0.23)	0.37	0.0334	(3.87)	(3.67)
Return On Tangible Assets	(1.31)	(0.25)	(0.49)	(0.68)	(0.78)	(0.82)
Ev To Free Cash Flow	(0.52)	(0.21)	0.37	0.0332	(3.83)	(3.64)
Net Debt To E B I T D A	0.57	2.63	0.91	1.29	0.92	0.87
Current Ratio	5.16	10.95	5.91	7.19	4.98	8.77
Enterprise Value Over E B I T D A	(0.3)	(0.24)	0.44	0.0267	(3.17)	(3.02)
Roic	(1.07)	(0.33)	(0.76)	(0.8)	(0.93)	(0.97)

Pair Trading with Jasper Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Jasper Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Jasper Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Jasper Stock

0.64	CDIOW	Cardio Diagnostics	Pair Corr
0.72	ELVN	Enliven Therapeutics	Pair Corr

Moving against Jasper Stock

0.82	GE	GE Aerospace	Pair Corr
0.79	PLX	Protalix Biotherapeutics	Pair Corr
0.76	WM	Waste Management	Pair Corr
0.6	LUCD	Lucid Diagnostics	Pair Corr
0.5	MLSS	Milestone Scientific Earnings Call Today	Pair Corr

The ability to find closely correlated positions to Jasper Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Jasper Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Jasper Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Jasper Therapeutics to buy it.

The correlation of Jasper Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Jasper Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Jasper Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Jasper Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Jasper Stock Analysis

When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Inventory Turnover	Net Income Per Share
Days Of Inventory On Hand	Payables Turnover
Sales General And Administrative To Revenue	Average Inventory
Research And Ddevelopement To Revenue	Capex To Revenue
Cash Per Share	Pocfratio
Interest Coverage	Payout Ratio
Capex To Operating Cash Flow	Pfcf Ratio
Days Payables Outstanding	Net Current Asset Value
Income Quality	Roe
Tangible Asset Value	Ev To Operating Cash Flow
Pe Ratio	Return On Tangible Assets
Ev To Free Cash Flow	Earnings Yield
Intangibles To Total Assets	Net Debt To E B I T D A
Current Ratio	Tangible Book Value Per Share
Receivables Turnover	Graham Number
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Roic
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Jasper Historical Financial Ratios

About Jasper Financial Ratios Analysis

Jasper Therapeutics Financial Ratios Chart

Payables Turnover

Income Quality

Jasper Therapeutics fundamentals Correlations

Jasper Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Jasper Therapeutics fundamentals Accounts

Pair Trading with Jasper Therapeutics

Moving together with Jasper Stock

Moving against Jasper Stock

Additional Tools for Jasper Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Cash Per Share	+ 1.0	Capex To Depreciation
Days Of Inventory On Hand	+ 1.0	Inventory Turnover
Days Payables Outstanding	+ 1.0	Inventory Turnover
Days Payables Outstanding	+ 1.0	Days Of Inventory On Hand

Capex To Operating Cash Flow	- 1.0	Cash Per Share
Days Payables Outstanding	- 1.0	Net Income Per Share
Days Of Inventory On Hand	- 1.0	Net Income Per Share
Net Income Per Share	- 1.0	Inventory Turnover
Capex To Operating Cash Flow	- 1.0	Capex To Depreciation
Days Payables Outstanding	- 0.98	Free Cash Flow Per Share